Epitomee Medical Ltd Cash Flow Conversion Efficiency
Epitomee Medical Ltd cash flow conversion efficiency. Based on the latest financial reports, Epitomee Medical Ltd (EPIT) has a cash flow conversion efficiency ratio of -0.416x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-12.78 Million ≈ $-34.27K USD) by net assets (ILA30.72 Million ≈ $82.35K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Epitomee Medical Ltd (2019–2024)
Cash flow conversion efficiency of Epitomee Medical Ltd from 2019 to 2024. This chart illustrates how Epitomee Medical Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View EPIT live share price for real-time trading data and today's change.
Epitomee Medical Ltd Cash Flow Conversion Ratio Explained
Epitomee Medical Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Epitomee Medical Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Epitomee Medical Ltd ranked by their cash flow conversion efficiency. Also see how much is Epitomee Medical Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pasdec Holdings Bhd
KLSE:6912
|
-0.022x |
|
TPC Mechatronics Corporation
KQ:048770
|
-0.010x |
|
Profoto Holding AB
ST:PRFO
|
0.022x |
|
SEKONIX Co. Ltd
KQ:053450
|
-0.010x |
|
Navamedic ASA
OL:NAVA
|
0.019x |
|
Beyaz Filo Oto Kiralama AS
IS:BEYAZ
|
0.347x |
|
MicroAlgo Inc.
NASDAQ:MLGO
|
0.006x |
|
ML System S.A.
WAR:MLS
|
-0.076x |
Annual Cash Flow Conversion Efficiency for Epitomee Medical Ltd (2019–2024)
The table below shows the annual cash flow conversion efficiency of Epitomee Medical Ltd from 2019 to 2024. Review cash generation quality of Epitomee Medical Ltd to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA33.95 Million ≈ $91.02K |
ILA-8.29 Million ≈ $-22.23K |
-0.244x | -7.30% |
| 2023-12-31 | ILA34.80 Million ≈ $93.30K |
ILA-7.92 Million ≈ $-21.24K |
-0.228x | +4.69% |
| 2022-12-31 | ILA39.45 Million ≈ $105.75K |
ILA-9.42 Million ≈ $-25.26K |
-0.239x | -121.08% |
| 2021-12-31 | ILA53.30 Million ≈ $142.89K |
ILA-5.76 Million ≈ $-15.44K |
-0.108x | -106.37% |
| 2020-12-31 | ILA3.98 Million ≈ $10.66K |
ILA6.75 Million ≈ $18.09K |
1.697x | +519.62% |
| 2019-12-31 | ILA6.89 Million ≈ $18.49K |
ILA-2.79 Million ≈ $-7.47K |
-0.404x | -- |
About Epitomee Medical Ltd
Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. It offers capsules, which are polymer-based scaffold for controlled delivery of therapies along the GI tract for weight management and biologics delivery. The company was incorporated in 2005 and is based in Caesarea, Israel.